Trending Now - Bristol Myers Secures $15.2B Licensing Agreement With Hengrui

WHO:

Endpoints News - Bristol-Myers Squibb Co. and Jiangsu Hengrui Pharmaceuticals Co. are involved in the licensing agreement.

Bloomberg Markets - Bristol-Myers Squibb Co. is a US drugmaker.

WHAT:

Endpoints News - Bristol-Myers Squibb has entered into a 13-asset deal with Hengrui that could be worth up to $15.2 billion.

Bloomberg Markets - The collaboration and licensing deal with Hengrui could be valued at as much as $15.2 billion.

WHERE:

Endpoints News - The deal involves Jiangsu Hengrui Pharmaceuticals, which is located in China.

WHEN:

Bloomberg Markets - The deal is part of Bristol-Myers' strategy to leverage China's efficiency in early development.

WHY:

Bloomberg Markets - The motivation behind the deal is for Bristol-Myers to capitalize on the efficiency of Hengrui in early drug development.

HOW:

Endpoints News - The agreement includes a collaboration and licensing framework for 13 assets.

(UPDATED May 12, 2026 17:42 UTC)

Bristol-Myers Squibb has entered into a significant licensing agreement with Jiangsu Hengrui Pharmaceuticals that could be valued at up to $15.2 billion. This collaboration involves a framework for 13 assets and aims to leverage Hengrui's efficiency in early drug development, which is part of Bristol-Myers' broader strategy. The deal highlights the growing partnership between a major U.S. drugmaker and a prominent Chinese pharmaceutical company.